ASSESSMENT OF ANTIISCHEMIC AND ANTIANGINAL EFFECTS OF NICORANDIL BY TREADMILL TEST, UNDER THE FRAMEWORK OF KVAZAR STUDY
Aim. Under the framework of KVAZAR study, to assess antianginal and antiischemic effects of nicorandil therapy with exercise test on treadmill in chronic coronary heart disease patients (CCHD) with stable angina.Material and methods. Randomized, double blind, placebo-control study, conducted in 2 pa...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2017-03-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1604 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim. Under the framework of KVAZAR study, to assess antianginal and antiischemic effects of nicorandil therapy with exercise test on treadmill in chronic coronary heart disease patients (CCHD) with stable angina.Material and methods. Randomized, double blind, placebo-control study, conducted in 2 parallel groups, multicenter. Totally, 120 patients included, all were taking metoprolol tartrat 50 mg b.i.d. After randomization, main group was added nicorandil 10 mg b.i.d., in 2 weeks the dosage was increased to 20 mg b.i.d., control took placebo. Duration of the study 6 weeks. For the evaluation of efficacy of nicorandil therapy 10-20 mg b.i.d., exercise test was used, done at randomization visit (V0) and in 6 weeks (V6).Results. Intake of nicorandil, in 6 weeks was followed by a significant increase of the time before the onset of angina (p<0,0001), time to ST depression appearance for 1 mm (p<0,005) and time for angina attack of moderate severity development (p<0,005). In placebo group, only the angina onset tolerance parameter improved (p<0,01), but duration of exercise test and time for ST depression 1 mm did not change significantly. In the subgroup of patients having ischemic ECG changes during exercise test, it was showed significant increase of these changes in nicorandil vs placebo (p<0,05); which confirms the anti-ischemic action of nicorandil during the day in double dosing regimen. Conclusion. Nicorandil did statistically significantly improve the parameters of exercise tolerance in CCHD patients with stable angina. The results of the study make it to conclude on the additional and clinically significant impact of the drug 10-20 mg b.i.d. as an effective antianginal medication of second-line therapy for treatment of patients with CCHD with stable angina. |
|---|---|
| ISSN: | 1560-4071 2618-7620 |